Composition for assisting in reducing blood fat

Abstract

The invention provides a composition which is composed of probiotics, a lotus leaf extract, a white kidney bean extract and a cranberry extract, and further relates to application of the composition in preparation of products for assisting in reducing blood fat. All the components in the composition provided by the invention form a compound according to a certain proportion, the composition has the effect of synergistically reducing blood fat, and the compound form is beneficial to improving the taking compliance.

Description

Technical Field

[0001] The present invention relates to a composition containing probiotics, lotus leaf extract, white kidney bean extract and cranberry extract and its use, which is used for assisting in lowering blood lipids. The present invention belongs to the field of health food. Background Art

[0002] With the improvement of living standards and changes in dietary structure, high blood lipids have troubled the Chinese people. Statistics from the National Center for Cardiovascular Diseases show that the number of people with abnormal blood lipids in my country has exceeded 400 million. At the same time, the population with abnormal blood lipids is getting younger, and the population aged 30 to 50 years old is "coming from behind". High blood lipids are an important risk factor for cardiovascular disease. Therefore, blood lipid management is one of the key points of cardiovascular disease prevention and control in my country.

[0003] Clinically, chemical drugs for treating hyperlipidemia usually have side effects of varying degrees. For example, statins and fibrates are found to easily cause liver damage (elevated liver enzymes) in clinical applications, and some patients also experience serious adverse reactions such as rhabdomyolysis. Therefore, chemical drugs for lipid-lowering treatment need to be carefully selected, especially the risk of side effects, which is a problem that needs to be solved.

[0004] Probiotics are a type of active microorganisms that are beneficial to the human body. By colonizing in the human body, they change the composition of the flora in a certain part of the host. Probiotics can be single microorganisms or mixed microorganisms with clear ingredients. Probiotics promote nutrient absorption and maintain intestinal health by regulating the host mucosal and systemic immune functions or regulating the balance of intestinal flora. Although there are studies on probiotics in lowering blood lipids, their specific mechanism of action in lowering blood lipids is still unclear, and the physiological functions of probiotics of different genera, different species, and even different strains vary greatly. The complex microecological system composed of different types of probiotics is even more difficult to predict. In probiotic preparations, prebiotics are usually combined for compound preparations. Different probiotics use different active metabolites produced by prebiotics, resulting in overall functional differences. Therefore, the development of a probiotic product with a synergistic lipid-lowering effect can make up for the shortcomings of chemical lipid-lowering treatment (especially the risk of side effects), and therefore has clinical application value. Summary of the invention

[0005] In order to solve the shortcomings of the above-mentioned chemical drugs for treating hyperlipidemia and meet clinical needs, the present invention provides a composition containing probiotics, lotus leaf extract, white kidney bean extract, and cranberry extract and a preparation method thereof, and the specific technical scheme involved is:

[0006] A composition comprising:

[0007] (1) Probiotics,

[0008] (2) Lotus leaf extract,

[0009] (3) White Kidney Bean Extract,

[0010] (4) Cranberry extract,

[0011] (5) Prebiotics,

[0012] (6) Auxiliary materials.

[0013] The composition of the present invention contains, by weight, 100-500 parts of probiotics, 100-500 parts of lotus leaf extract, 500-1000 parts of white kidney bean extract and 100-500 parts of cranberry extract.

[0014] The composition described in the present invention preferably contains, by weight, 200-300 parts of probiotics, 300-400 parts of lotus leaf extract, 500-700 parts of white kidney bean extract, and 300-500 parts of cranberry extract.

[0015] In the composition described in the present invention, the probiotics are one or more of Bifidobacterium lactis, Bifidobacterium longum BL21, Lactobacillus plantarum LP90, Lactobacillus casei, and Bifidobacterium bifidum.

[0016] In the composition described in the present invention, preferably, the probiotics are one or both of Bifidobacterium longum BL21 and Lactobacillus plantarum LP90.

[0017] In the composition described in the present invention, the prebiotics are one or more of inulin, oligofructose, galacto-oligosaccharide, glucopyrano-oligosaccharide, xylo-oligosaccharide, arabinogalactan, glucomannan and galactomannan.

[0018] In the composition described in the present invention, the prebiotics are preferably one or more of fructooligosaccharides, galacto-oligosaccharides and inulin.

[0019] In the composition of the present invention, the prebiotics are preferably one or more of 2000-3000 parts of oligofructose, 500-1000 parts of oligogalactose, and 2000-3000 parts of inulin, based on weight.

[0020] The composition according to any one of the present invention is characterized in that its preparation form includes solid beverages, tablets, capsules, gels, powders, pills, fruit drinks, candy bars, yogurt drinks, fermented dairy products, meal replacements, ice cream, cheese or milkshakes.

[0021] Use of the composition described in any one of the present invention in the preparation of a product for assisting in lowering blood lipids.

[0022] Use of the composition described in any one of the present invention in preparing a solid beverage for assisting in lowering blood lipids.

[0023] In the present invention, a portion may be micrograms, milligrams, grams, microliters, milliliters, deciliters, etc.

[0024] The composition provided by the present invention has the advantages of selecting specific probiotics with lipid-lowering function and plant extracts for scientific proportion, including lotus leaf extract, white kidney bean extract, and cranberry extract, and the composition has significant effects on reducing blood lipids and body weight. Experiments have proved that the combination of probiotics and one or more plant extracts has a synergistic effect of reducing blood lipids, and has no safety risks, which makes up for the shortcomings of existing lipid-lowering drugs and has clinical application value. Specific embodiments

[0025] The present invention is further described below in conjunction with specific implementation modes, which is not intended to limit the present invention. Any equivalent replacements in the art made according to the contents of the present invention shall fall within the protection scope of the present invention.

[0026] The raw materials and excipients used in the composition, use and health care products provided by the present invention can all be purchased from the market. Among them, white kidney bean extract was purchased from Shanghai Weiqing Biotechnology Co., Ltd., lotus leaf powder extract was purchased from Guangdong Qingyunshan Pharmaceutical Co., Ltd., cranberry extract was purchased from Tianjin Tangchao Food Industry Co., Ltd., and probiotics were purchased from Weikang Probiotics (Suzhou) Co., Ltd. The total amount of probiotics of Bifidobacterium lactis, Bifidobacterium longum BL21, Lactobacillus plantarum LP90, Lactobacillus casei, and Bifidobacterium bifidum was not less than 10 6 CFU / g.

[0027] Example 1: Effect of the composition of the present invention on blood lipid levels in hyperlipidemic SD model rats

[0028] This experiment used SD rats, half male and half female, 8 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., with free access to food and water, and light exposure of 12h / 12h. They were included in the experiment after 7 days of quarantine.

[0029] Ten normal healthy rats, half male and half female, were selected as the control group. During the experiment, they were always fed with ordinary feed and had free access to water.

[0030] The hyperlipidemia rat model was prepared by feeding the rats with a high-fat diet (10% hydrogenated coconut oil, 1% cholesterol, 89% basal diet).

[0031] Rats were fed with the above high-fat formula feed for modeling. After 6 weeks, blood was collected from all rats to measure the levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC). The rats with successful modeling (LDL-C increased by more than 20%) were randomly divided into a model group and an intervention group according to the LDL-C level, taking into account the TC level. The intervention group was given the composition and its single agents provided in the present invention (the probiotic group was a mixture of Bifidobacterium lactis, Bifidobacterium longum BL21, Lactobacillus plantarum LP90, Lactobacillus casei, and Bifidobacterium bifidum) by gavage at a volume of 10 ml / kg once a day. The control group and the model group were given the corresponding volume of deionized water.

[0032] After 8 weeks of drug administration, blood was collected to measure the levels of LDL-C and TC.

[0033] The Kimura Q value method, also known as the probability addition method, calculates Q = E A+B / (E A +E B -E A ×E B ) according to the pharmacological effects of the combination of two drugs and the pharmacological effects of the two drugs used alone in the dose-effect curve area. In the formula, the numerator represents the "measured combined effect", the denominator represents the "expected combined effect", and Q is the ratio of the two. When the Q value < 0.85, the combination of the two drugs is considered an antagonistic effect; when 0.85 < Q value < 1.15, it is considered an additive effect; when the Q value > 1.15, it is considered a synergistic effect. To meet the analysis of the pharmacological effect relationship, the measured values are converted into effects that can intuitively reflect the strength of the pharmacological effect. The calculation formula: E i =(1 - P i / P 模型组 )×100%, where P i is the measured value of each group, and P 模型组 is the measured value of the model group.

[0034] The test results after 8 weeks of drug administration are shown in the following table.

[0035] Table 1: Effects of the composition of the present invention on the blood lipid levels of high-fat diet-induced SD rats ( n = 10)

[0036]

[0037] Compared with the control group, ## P < 0.01; compared with the model group, * P < 0.05, ** P < 0.01.

[0038] From the above experimental results, it can be concluded that the levels of LDL-C and TC in the probiotics group, lotus leaf extract group, white kidney bean extract group, and cranberry extract group were significantly reduced compared with the model group. The combination of probiotics and lotus leaf extract can significantly further reduce the levels of LDL-C and TC, with significant statistical differences compared with the model group. The Q value effect analysis shows that probiotics and lotus leaf extract have a synergistic effect in regulating blood lipids.

[0039] Adding white kidney bean extract to the probiotics + lotus leaf extract further enhances its lipid-lowering effect and has a synergistic effect. Further adding cranberry extract has the best lipid-lowering effect and also has a synergistic effect.

[0040] Example 2: Effect of the composition of the present invention on blood lipid levels in hyperlipidemia model golden hamsters

[0041] In the experiment, a hyperlipidemia model was prepared by feeding golden hamsters with a high-fat diet, and then the corresponding composition provided by the present invention was given to evaluate its effect of reducing blood lipids.

[0042] Golden hamsters, SPF grade, 8 weeks old, 120-140 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., with free access to food and water, and light exposure alternating 12h / 12h. They were included in the experiment after 7 days of quarantine.

[0043] Ten golden hamsters were randomly selected and fed with ordinary feed until the end of the experiment as the control group, and the remaining hamsters were fed with high-fat feed (10% hydrogenated coconut oil, 1% cholesterol, 89% basic feed) for modeling for 8 weeks. After the end, blood was collected from the orbits of all hamsters to determine their LDL-C and TC levels. Animals whose LDL-C levels were increased by more than 20% after high-fat diet feeding were selected. They were randomly stratified into a model group and a drug-treated group according to their LDL-C levels and TC levels. The groups and drug dosages are shown in the table below (the probiotic group was a mixture of Bifidobacterium longum BL21 and Lactobacillus plantarum LP90). The gavage volume was 10 ml / kg, once a day, and the control group and the model group were given corresponding volumes of deionized water.

[0044] After 8 weeks of administration, blood was collected from all hamsters to measure LDL-C and TC levels. The results are shown in the following table:

[0045] Table 2: Effects of the composition of the present invention on blood lipid levels in golden hamsters with high fat diet ( n=10)

[0046]

[0047]

[0048] Compared with the control group, ##P<0.01; compared with the model group, * P<0.05, ** P<0.01.

[0049] From the above experimental results, the probiotic group, lotus leaf extract group, white kidney bean extract group, and cranberry extract group showed significant decreases in LDL-C and TC levels compared with the model group. The combination of probiotics and white kidney bean extract can significantly further reduce LDL-C and TC levels, with significant statistical differences compared with the model group. The Q value effect analysis showed that probiotics and white kidney bean extract have a synergistic effect in regulating blood lipids. Adding cranberry extract to the probiotic + white kidney bean extract has further enhanced its blood lipid-lowering effect and has a synergistic effect. Further adding lotus leaf extract has the best blood lipid-lowering effect and also has a synergistic effect.

[0050] The above experimental results show that the probiotic composition provided by the present invention has a definite lipid-lowering effect, and there is a synergistic effect between the probiotics and the selected nutritional extracts, and it has a good effect in clinical use to assist in lowering blood lipids.

Claims

1. A composition comprising: (1) Probiotics, (2) Lotus leaf extract, (3) White Kidney Bean Extract, (4) Cranberry extract, (5) Prebiotics, (6) Auxiliary materials.

2. The composition according to claim 1, characterized in that Calculated by weight, it contains 100-500 parts of probiotics, 100-500 parts of lotus leaf extract, 500-1000 parts of white kidney bean extract and 100-500 parts of cranberry extract.

3. The composition according to claim 2, characterized in that Calculated by weight, it contains 200-300 parts of probiotics, 300-400 parts of lotus leaf extract, 500-700 parts of white kidney bean extract and 300-500 parts of cranberry extract.

4. The composition according to claim 1, characterized in that The probiotics are one or more of Bifidobacterium lactis, Bifidobacterium longum BL21, Lactobacillus plantarum LP90, Lactobacillus casei, and Bifidobacterium bifidum.

5. The composition according to claim 1, characterized in that Preferably, the probiotics are one or both of Bifidobacterium longum BL21 and Lactobacillus plantarum LP90.

6. The composition according to claim 1, characterized in that The prebiotics are one or more of inulin, oligofructose, galacto-oligosaccharide, glucopyrano-oligosaccharide, xylo-oligosaccharide, arabinogalactan, glucomannan and galactomannan.

7. The composition according to claim 6, characterized in that The prebiotics are one or more of fructooligosaccharides, galacto-oligosaccharides and inulin.

8. The composition according to claim 7, characterized in that In parts by weight, the prebiotics are one or more of 2000-3000 parts of oligofructose, 500-1000 parts of oligogalactose, and 2000-3000 parts of inulin.

9. The composition according to any one of claims 1 to 8, characterized in that The preparation forms include solid drinks, tablets, capsules, gels, powders, pills, fruit drinks, candy bars, yogurt drinks, fermented dairy products, meal replacements, ice cream, cheese or milkshakes.

10. Use of the composition according to any one of claims 1 to 8 in the preparation of a product for assisting in lowering blood lipids.

Images